 |
 |
Raising Awareness of a Newly Public Company's Drug Conjugate Technology
Following a successful IPO in 2011, Endocyte sought to raise awareness of the company's technology instead of just its share price. The company approached Russo Partners to develop a strategy and implement a PR program that would generate awareness of its unique drug conjugate technology.
READ MORE.
|
|
|
|
 |
|
Expanding a European Biotech Company's Profile in the Home Country and Beyond
Germany-based CureVac is developing an entirely new class of therapies that harness the medical potential of messenger RNA. When the company looked to attract potential partners and generate interest in CureVac's technology among the global medical community it turned to Russo Partners to increase its visibility within and outside of Germany.
READ MORE.
|
|
|
|
 |
|
Building a Corporate Profile After a Change in Business Direction
Following a shift in its business strategy, Flexion Therapeutics enlisted Russo Partners to help build the company's corporate profile through a rigorous messaging process and to increase its visibility through proactive media relations program.
READ MORE.
|
|
|
|
 |
|
Generating Awareness of a Non-Invasive Prenatal Diagnostic Test in a Crowded Market
While advancing a next-generation, non-invasive prenatal test toward the market, Natera found itself behind multiple companies gearing up to launch similar diagnostic products. Natera approached Russo Partners to implement a leadership-positioning communications program to stake its claim in the space and generate interest among investors prior to its own product launch.
READ MORE.
|
|
|
|
 |
|
Repairing Disconnects with the Investment Community through Integrated Corporate Communications
In advance of a pivotal Phase 3 data announcement for its now-approved obesity drug, BELVIQ, Arena Pharmaceuticals called on Russo Partners to build a framework for communicating positive clinical trial results that had previously been misunderstood by the investment and business development communities.
READ MORE.
|
|
|
|
 |
|
Building an IR Program From the Ground Up at the Time of an IPO
Cempra is focused on developing differentiated antibiotics to address the rising prevalence of drug-resistant pathogens that are increasing the challenge of treating bacterial infections. Its two lead candidates, solithromycin and Taksta(TM), are in advanced clinical development. The company successfully completed an initial public offering in February 2012 to help fund both of these programs.
READ MORE.
|
|
|
|
 |
|
Building a Presence in the U.S. Investment Community for a Canadian Medtech Company
Sernova is a Canadian medical device company developing products for chronic diseases using therapeutic cells transplanted into an implanted medical device. Sernova entered into Phase 1 clinical trials with its first products for the treatment of insulin-dependent diabetes and approached Russo Partners to build awareness of the company and its technology with the U.S. investment community.
READ MORE.
|
|
|
|
 |
|
Breaking Through the Stem Cell Noise for Leadership Positioning
StemCells Inc. is an adult stem cell therapeutics company focused on developing treatments for CNS disorders. Upon finding itself in the shadows of its competitors in terms of media coverage, the company engaged Russo Partners to improve its visibility among the investment and medical communities.
READ MORE.
|
|
|
|
 |
|
Supporting Business Development for a Unique Protein Drug Optimization Technology
Ambrx made a fundamental advance in protein biosynthesis that enabled scientists to modify existing protein drugs. Now the company needed to optimize its messaging and complement its reach through PR initiatives targeting prospective investors and partners.
READ MORE.
|
|
|
|
 |
|
Enabling New Genome Sequencing Technology to Stand Out in a Crowd
When 454 Life Sciences began developing a next-generation genome sequencer, it was one of several firms working on technology that would reduce the time and cost of sequencing. The company wanted to stand out in a crowded field.
READ MORE.
|
|
|
|
 |
|
Bringing a Biopharmaceutical Company Across the Border
Helix BioPharma is a Canadian-based biopharmaceutical company that specializes in the field of cancer therapy. With a base of investors in Canada and Europe, the company sought to build its following in the U.S.
READ MORE.
|
|
|
|
 |
|
Introducing a Novel Medical Device to the World
OrbusNeich developed a new cardiac stent unlike any other product on the market. With the stent available in Europe, Asia and Latin America, OrbusNeich approached Russo Partners with the specific goal of generating visibility in the medical community to drive sales.
READ MORE.
|
